Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 77.02
CNAT's Cash-to-Debt is ranked higher than
51% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CNAT: 77.02 )
Ranked among companies with meaningful Cash-to-Debt only.
CNAT' s Cash-to-Debt Range Over the Past 10 Years
Min: 8.03  Med: 36.79 Max: 77.02
Current: 77.02
8.03
77.02
Equity-to-Asset 0.27
CNAT's Equity-to-Asset is ranked lower than
85% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CNAT: 0.27 )
Ranked among companies with meaningful Equity-to-Asset only.
CNAT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.27 Max: 0.27
Current: 0.27
Piotroski F-Score: 5
Altman Z-Score: -1.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3733.79
CNAT's Operating Margin % is ranked lower than
87% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CNAT: -3733.79 )
Ranked among companies with meaningful Operating Margin % only.
CNAT' s Operating Margin % Range Over the Past 10 Years
Min: -3733.79  Med: -3733.67 Max: -3733.67
Current: -3733.79
-3733.79
-3733.67
Net Margin % -3721.40
CNAT's Net Margin % is ranked lower than
87% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CNAT: -3721.40 )
Ranked among companies with meaningful Net Margin % only.
CNAT' s Net Margin % Range Over the Past 10 Years
Min: -3721.4  Med: -3721.28 Max: -3721.28
Current: -3721.4
-3721.4
-3721.28
ROE % -103.43
CNAT's ROE % is ranked lower than
80% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CNAT: -103.43 )
Ranked among companies with meaningful ROE % only.
CNAT' s ROE % Range Over the Past 10 Years
Min: -105.57  Med: -71.28 Max: -51.71
Current: -103.43
-105.57
-51.71
ROA % -66.57
CNAT's ROA % is ranked lower than
77% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CNAT: -66.57 )
Ranked among companies with meaningful ROA % only.
CNAT' s ROA % Range Over the Past 10 Years
Min: -70.74  Med: -55.25 Max: -46.8
Current: -66.57
-70.74
-46.8
ROC (Joel Greenblatt) % -9643.37
CNAT's ROC (Joel Greenblatt) % is ranked lower than
87% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CNAT: -9643.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CNAT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -57184.91  Med: -25575.34 Max: -8274.57
Current: -9643.37
-57184.91
-8274.57
3-Year EBITDA Growth Rate -14.10
CNAT's 3-Year EBITDA Growth Rate is ranked lower than
68% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CNAT: -14.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CNAT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -50.4  Med: -46.7 Max: -14.1
Current: -14.1
-50.4
-14.1
3-Year EPS without NRI Growth Rate 27.60
CNAT's 3-Year EPS without NRI Growth Rate is ranked higher than
80% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CNAT: 27.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CNAT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.5  Med: -46.7 Max: 27.6
Current: 27.6
-50.5
27.6
GuruFocus has detected 3 Warning Signs with Conatus Pharmaceuticals Inc $CNAT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CNAT's 10-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CNAT Guru Trades in Q4 2015

Jim Simons 33,786 sh (New)
Steven Cohen 328,300 sh (New)
» More
Q1 2016

CNAT Guru Trades in Q1 2016

Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q3 2016

CNAT Guru Trades in Q3 2016

Jim Simons 62,600 sh (New)
» More
Q4 2016

CNAT Guru Trades in Q4 2016

Jim Simons 183,700 sh (+193.45%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CNAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:VRACY, NAS:PETX, NAS:CEMP, NAS:CDXS, NAS:PTI, NAS:NVLN, NAS:PPHM, OTCPK:BNRPF, NAS:CLSD, NAS:ABEO, NAS:ENZY, OTCPK:SPRWF, NAS:CASC, OTCPK:BCDA, OTCPK:TRGNF, NAS:FATE, NAS:KURA, NAS:MNOV, NAS:ATHX, NYSE:KDMN » details
Traded in other countries:CPH.Germany,
Headquarter Location:USA
Conatus Pharmaceuticals Inc is a biotechnology company. It is engaged in the development and commercialization of novel medicines to treat liver disease.

Conatus Pharmaceuticals Inc was incorporated under the laws of the state of Delaware on July 13, 2005. It is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. The Company's compound, emricasan, is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases, which are enzymes that mediate inflammation and apoptosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that play the role of modulators of critical cellular functions, including functions that result in apoptosis and inflammation. Caspase activation and regulation is tightly controlled through a number of mechanisms. All caspases are expressed as enzymatically inactive forms known as pro-caspases, which can be activated following a variety of cellular insults or stimuli. The Company operates in one business segment, which is the commercialization and development of pharmaceutical products. The Company's potential competitors include multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. The Company has received three United States patents and corresponding foreign patents and patent applications directed to the composition of matter. Foreign patents have been granted in Australia, Austria, Belgium, Canada, China, Denmark, Europe, Finland, France, Germany, Great Britain, Greece, Hong Kong, India, Ireland, Israel, Italy, Japan, Luxembourg, Mexico, Netherlands, Portugal, Singapore, South Africa, South Korea, Spain, Sweden and Switzerland. A patent application is pending in Poland. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales, promotion and distribution of its products.

Top Ranked Articles about Conatus Pharmaceuticals Inc

Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients, Including NASH Patients, Awaiting Liver Transplantation
Conatus to Present at Upcoming Investor Conferences

SAN DIEGO, March 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the company’s scheduled presentations at two upcoming investor conferences in New York:
H.C. Wainwright NASH Investor Conference at 2:20 p.m. ET on Monday, April 3.
 16th Annual Needham Healthcare Conference at 3:00 p.m. ET on Tuesday, April 4. Webcasts of both conference presentations will be available in the Investors section of the company’s website at www.conatuspharma.com. About Conatus Pharmaceuticals
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com. Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding emricasan’s potential to interrupt the disease progression across the spectrum of liver disease. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT: Alan Engbring
Conatus Pharmaceuticals Inc.
(858) 376-2637
[email protected]

Read more...
Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results

SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2016, after the market close on Wednesday, March 15, 2017. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Wednesday, March 15, 2017, to discuss the financial results and provide a corporate update.
To access the conference call, please dial 877-312-5857 (domestic) or 970-315-0455 (international) at least five minutes prior to the start time and refer to conference ID 75917141. A live and archived audio webcast of the call will also be available in the Investors section of the Conatus website at www.conatuspharma.com. About Conatus Pharmaceuticals
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com. Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding emricasan’s potential to interrupt the disease progression across the spectrum of liver disease. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT: Alan Engbring
Conatus Pharmaceuticals Inc.
(858) 376-2637
[email protected]


Read more...

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 8.19
CNAT's Price-to-Owner-Earnings is ranked higher than
90% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. CNAT: 8.19 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CNAT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.73  Med: 4.66 Max: 8.19
Current: 8.19
1.73
8.19
PB Ratio 10.15
CNAT's PB Ratio is ranked lower than
75% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CNAT: 10.15 )
Ranked among companies with meaningful PB Ratio only.
CNAT' s PB Ratio Range Over the Past 10 Years
Min: 2.14  Med: 5.77 Max: 10.15
Current: 10.15
2.14
10.15
PS Ratio 242.86
CNAT's PS Ratio is ranked lower than
89% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CNAT: 242.86 )
Ranked among companies with meaningful PS Ratio only.
CNAT' s PS Ratio Range Over the Past 10 Years
Min: 51.14  Med: 137.71 Max: 242.86
Current: 242.86
51.14
242.86
Price-to-Free-Cash-Flow 7.45
CNAT's Price-to-Free-Cash-Flow is ranked higher than
91% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. CNAT: 7.45 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CNAT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.57  Med: 4.22 Max: 7.45
Current: 7.45
1.57
7.45
Price-to-Operating-Cash-Flow 7.41
CNAT's Price-to-Operating-Cash-Flow is ranked higher than
91% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. CNAT: 7.41 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CNAT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.56  Med: 4.19 Max: 7.41
Current: 7.41
1.56
7.41
EV-to-EBIT -3.15
CNAT's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CNAT: -3.15 )
Ranked among companies with meaningful EV-to-EBIT only.
CNAT' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.2  Med: -1.1 Max: 1.2
Current: -3.15
-3.2
1.2
EV-to-EBITDA -3.19
CNAT's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CNAT: -3.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
CNAT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.2  Med: -1.1 Max: 1.2
Current: -3.19
-3.2
1.2
Current Ratio 2.03
CNAT's Current Ratio is ranked lower than
74% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CNAT: 2.03 )
Ranked among companies with meaningful Current Ratio only.
CNAT' s Current Ratio Range Over the Past 10 Years
Min: 2.03  Med: 9.37 Max: 20.2
Current: 2.03
2.03
20.2
Quick Ratio 2.03
CNAT's Quick Ratio is ranked lower than
70% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CNAT: 2.03 )
Ranked among companies with meaningful Quick Ratio only.
CNAT' s Quick Ratio Range Over the Past 10 Years
Min: 2.03  Med: 9.37 Max: 20.2
Current: 2.03
2.03
20.2
Days Sales Outstanding 1.00
CNAT's Days Sales Outstanding is ranked higher than
98% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CNAT: 1.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
CNAT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1  Med: 1142.05 Max: 1142.05
Current: 1
1
1142.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.60
CNAT's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CNAT: -18.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CNAT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -169.2  Med: -148.7 Max: -18.6
Current: -18.6
-169.2
-18.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 13.49
CNAT's Price-to-Net-Cash is ranked lower than
64% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. CNAT: 13.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CNAT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.82  Med: 2.67 Max: 13.49
Current: 13.49
1.82
13.49
Price-to-Net-Current-Asset-Value 11.18
CNAT's Price-to-Net-Current-Asset-Value is ranked lower than
59% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CNAT: 11.18 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CNAT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.71  Med: 2.62 Max: 11.18
Current: 11.18
1.71
11.18
Price-to-Tangible-Book 10.12
CNAT's Price-to-Tangible-Book is ranked lower than
66% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CNAT: 10.12 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CNAT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.66  Med: 2.59 Max: 10.12
Current: 10.12
1.66
10.12
Price-to-Median-PS-Value 1.76
CNAT's Price-to-Median-PS-Value is ranked lower than
66% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CNAT: 1.76 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CNAT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.11  Med: 1.11 Max: 1.76
Current: 1.76
1.11
1.76
Earnings Yield (Greenblatt) % -31.57
CNAT's Earnings Yield (Greenblatt) % is ranked lower than
89% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CNAT: -31.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CNAT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10823.06  Med: 0 Max: 0
Current: -31.57
-10823.06
0

More Statistics

Revenue (TTM) (Mil) $0.80
EPS (TTM) $ -1.31
Beta2.74
Short Percentage of Float4.90%
52-Week Range $1.45 - 8.47
Shares Outstanding (Mil)26.17

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 16 16 15
EPS ($) -0.80 -0.90 -0.75
EPS without NRI ($) -0.80 -0.90 -0.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:CNAT

Headlines

Articles On GuruFocus.com
Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirr Apr 21 2017 
Conatus to Present at Upcoming Investor Conferences Mar 27 2017 
Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results Mar 08 2017 

More From Other Websites
Conatus (CNAT) Catches Eye: Stock Moves Up 10% in Session Apr 27 2017
Today's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sonus Networks Apr 27 2017
Conatus (CNAT) Up 57.7% Since Earnings Report: Can It Continue? Apr 26 2017
Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver... Apr 21 2017
Are Options Traders Betting on a Big Move in Conatus Pharmaceuticals (CNAT) Stock? Apr 17 2017
Conatus Pharmaceuticals and MannKind Look Forward to Promoting Their Brand Apr 03 2017
Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst' Mar 30 2017
Conatus to Present at Upcoming Investor Conferences Mar 27 2017
Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4 Mar 16 2017
Conatus reports 4Q loss Mar 15 2017
Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates Mar 15 2017
Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results Mar 08 2017
Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store? Feb 28 2017
Conatus Pharmaceuticals Appoints William R. LaRue as Independent Board Member Feb 07 2017
Conatus to Present at BIO CEO & Investor Conference Feb 06 2017
Conatus Pharmaceuticals Promotes Daniel L. Ripley to Senior Vice President, Business Development,... Feb 02 2017
Short Interest In Conatus Pharmaceuticals Surges Jan 13 2017
Henry Schein Hurt by Higher Costs, Lacks Growth Drivers Jan 12 2017
Walgreens Teams Up with Fedex to Boost Retail Performance Jan 12 2017
NuVasive at 52-Week High on Preliminary Results, MHLW Nod Jan 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)